Alcidion Group Ltd (ASX: ALC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Alcidion Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $141.01 million
P/E Ratio 83.33
Dividend Yield 0.00%
Shares Outstanding 1.34 billion
Earnings per share 0.001
Dividend per share N/A
Year To Date Return N/A
Earnings Yield 1.20%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Alcidion Group Ltd (ASX: ALC)
    Latest News

    a woman
    Share Gainers

    Why Alcidion, Jumbo, OM Holdings, & Resolute shares are racing higher

    The Jumbo Interactive Ltd (ASX:JIN) share price and the Resolute Mining Limited (ASX:RSG) share price are two of four racing…

    Read more »

    a woman
    Share Gainers

    Why this small cap ASX tech share jumped 5% higher today

    The Alcidion Group Ltd (ASX:ALC) share price is on course to end the week on a high. Here's why its…

    Read more »

    a woman
    Speculative

    Are these the best ASX small cap shares to buy in 2020?

    Are Audinate Group Limited (ASX:AD8) and these ASX small cap shares the best ones to own in 2020?

    Read more »

    a woman
    Speculative

    10 exciting small cap ASX shares to watch in 2020

    Audinate Group Limited (ASX:AD8), Serko Ltd (ASX:SKO), and these small cap ASX shares are the ones to watch in 2020...

    Read more »

    a woman
    Share Gainers

    Why this small cap ASX tech share is racing higher today

    The Alcidion Group Ltd (ASX:ALC) share price is charging higher on Thursday after announcing a new contract win with the…

    Read more »

    a woman
    Speculative

    10 exciting small cap ASX shares to watch in 2020

    Audinate Group Limited (ASX:AD8) and Opthea Ltd (ASX:OPT) are two of ten small cap ASX shares to watch closely in 2020...

    Read more »

    a woman
    Speculative

    5 exciting small cap ASX shares to watch in 2020

    Alcidion Group Ltd (ASX:ALC) and Bigtincan Holdings Ltd (ASX:BTH) are two of five exciting small cap ASX shares to watch in 2020...

    Read more »

    a woman
    ⏸️ ASX Shares

    3 exciting ASX healthcare shares to watch in 2020

    Nanosonics Ltd (ASX:NAN) shares are one of three that I think investors should watch closely in the healthcare sector...

    Read more »

    a woman
    Share Gainers

    Why the Alcidion share price jumped 8% higher today

    The Alcidion Group Ltd (ASX:ALC) share price has been a strong performer on Tuesday. Here's why this small cap tech…

    Read more »

    a woman
    Share Market News

    Insiders have been buying Suncorp and these ASX shares

    Suncorp Group Ltd (ASX:SUN) shares are one of three that insiders have been buying this month. Here's what you need…

    Read more »

    a woman
    Share Gainers

    Why Alcidion, Audinate, Jumbo, & Panoramic shares are racing higher today

    The Alcidion Group Ltd (ASX:ALC) share price and the Audinate Group Ltd (ASX:AD8) share price are two of four racing…

    Read more »

    a woman
    Share Gainers

    Why the Alcidion share price is surging higher on Tuesday

    The Alcidion Group Ltd (ASX:ALC) share price has surged higher after raising funds to fuel the healthcare technology company's growth...

    Read more »

    Frequently Asked Questions

    No, Alcidion does not pay dividends at this time.

    Alcidion listed on the ASX on 24 June 2011.

    ALC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Alcidion Group Ltd

    Alcidion Group Ltd (ASX: ALC) is a provider of intelligent informatics software for the healthcare sector.

    The company builds, sells, delivers, runs, and supports solutions for healthcare providers. These include clinical, analytical, managerial, and administrative systems.

    Its products include its Miya suite, a Fast Healthcare Interoperability Resources (FHIR) system that allows comprehensive healthcare data to be exchanged between different computer systems.  Other products include Smartpage and Patientrack software.

    Alcidion derives the majority of its revenue from its Australia/New Zealand segment and also has a presence in the United Kingdom.

    ALC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Feb 2026 $0.11 $0.00 0.00% 252,314 $0.11 $0.11 $0.11
    19 Feb 2026 $0.11 $0.00 0.00% 391,223 $0.11 $0.11 $0.11
    18 Feb 2026 $0.10 $0.00 0.00% 550,888 $0.10 $0.11 $0.10
    17 Feb 2026 $0.10 $0.00 0.00% 822,194 $0.11 $0.11 $0.10
    16 Feb 2026 $0.10 $0.00 0.00% 180,973 $0.11 $0.11 $0.10
    13 Feb 2026 $0.10 $-0.01 -9.09% 906,957 $0.11 $0.11 $0.10
    12 Feb 2026 $0.11 $0.01 9.52% 2,502,208 $0.11 $0.11 $0.11
    11 Feb 2026 $0.11 $-0.01 -9.09% 738,810 $0.11 $0.11 $0.11
    10 Feb 2026 $0.11 $0.00 0.00% 132,914 $0.11 $0.11 $0.11
    09 Feb 2026 $0.11 $0.01 9.52% 836,848 $0.11 $0.11 $0.11
    06 Feb 2026 $0.11 $0.00 0.00% 4,267,442 $0.11 $0.11 $0.10
    05 Feb 2026 $0.11 $-0.01 -9.09% 665,736 $0.12 $0.12 $0.11
    04 Feb 2026 $0.11 $-0.01 -8.70% 1,257,487 $0.12 $0.12 $0.11
    03 Feb 2026 $0.12 $0.00 0.00% 1,096,297 $0.12 $0.12 $0.12
    02 Feb 2026 $0.12 $0.00 0.00% 1,581,896 $0.12 $0.12 $0.12
    30 Jan 2026 $0.12 $0.00 0.00% 703,019 $0.12 $0.13 $0.12
    29 Jan 2026 $0.12 $-0.01 -8.00% 893,081 $0.13 $0.13 $0.12
    28 Jan 2026 $0.13 $0.00 0.00% 999,224 $0.13 $0.13 $0.12
    27 Jan 2026 $0.13 $0.00 0.00% 2,009,550 $0.13 $0.13 $0.12
    23 Jan 2026 $0.13 $0.01 8.33% 1,201,002 $0.13 $0.13 $0.12
    22 Jan 2026 $0.12 $0.00 0.00% 1,266,815 $0.13 $0.13 $0.12

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    04 Mar 2025 Katrina (Kate) Doyle (Quirke) Sell 5,000,000 $425,000
    Off-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Rebecca Jayne Wilson Non-Executive DirectorNon-Executive Chairman Jul 2017
    Ms Wilson is an experienced company director with private, ASX listed and not-for-profit organisations. In her previous executive career, she held global leadership roles in marketing communication, investor relations, and corporate affairs. She has experience in ESG stakeholder communication, issues, crisis and risk management, transactions, and investor relations. She has worked with multinational and growth companies in technology, healthcare, retail, and professional services sectors. Rebecca is experienced in leading companies during important commercial activation phases working with CEOs as both an advisor and non-executive director to develop and execute effective business strategy that supports accelerated and sustained growth. She's a Non-Executive Director of NFP, The Tomisich Foundation and Veski.
    Mr William (Bill) Smart Non-Executive Director Oct 2024
    Mr Smart is a global digital health leader with over 30 years of experience leading transformational change in organisations. Will has a track record of driving politically sensitive and operationally critical initiatives, enhancing organisational performance. Based in the United Kingdom, Will is currently Digital Non-Executive Director, Great Western Hospitals NHS Foundation Trust and was previously the CIO for Health and Social Care for England. In that role, Will provided advice to the Secretary of State for Health and Social Care and developed and delivered national strategies on information, technology and informatics. He has held executive roles in several NHS Trusts including as Group Chief Information Officer, Royal Free London NHS Foundation Trust. Until recently, Will served as the Global Director of External Relations, Dedalus Group where he had responsibilities across the UK and Europe and led the launch of their European built Electronic Patient Record (EPR) solution into Ireland and the UK. He is member of the Risk Committee.
    Ms Katrina (Kate) Elizabeth Doyle (Quirke) Chief Executive OfficerExecutive DirectorManaging Director Jul 2018
    Ms Doyle, since July 2018, has been the Group Managing Director and Chief Executive Officer of the Alcidion Group, a company dedicated to providing smart technology to the health sector. Kate leads the business globally with a goal of developing mutually beneficial relationships with customers, partners and investors. Kate has 25 plus years of digital health sector experience and has been involved in procurements and implementations of healthcare information technology across Australia, New Zealand, the United Kingdom and South-East Asia. Her background includes management roles at healthcare software firms where she has driven strategic product direction, global sales and operations. She believes technology can enable the transformation of healthcare delivery. Kate is currently a Non-Executive Director of ANDHealth, Australia's provider of accelerator, incubator and commercialisation programs for digital health technology companies.
    Mr Daniel Sharp Non-Executive Director Sep 2021
    Mr Sharp originally commencing his career as a lawyer and has over 25 years senior executive experience in investment banking and corporate finance. From 2012-2020, Danny was an Executive Director of Corporate Finance at Canaccord Genuity where he led dozens of equity capital market transactions and corporate finance advisory projects across the healthcare, life sciences, technologies, financial services and general industrials sectors. Prior to his executive role at Canaccord, Danny headed the corporate finance division at two of Australia's independent Investment Banking/Stockbroking firms. Danny has managed the IPOs, capital raisings and corporate advisory activities for ASX listed companies in the healthcare, technologies and general industrials sectors. He is connected to strong networks of institutional, family office and investors both in Australia and overseas. Danny is currently Non-Executive Chair of VetScripts Pty Ltd and a member of the Investment Committee for the Baker Heart and Diabetes Institute Foundation. He is chair of the Risk Committee.
    Professor Andrew Way Non-Executive Director Apr 2025
    Mr Way commenced his career as a nurse in the UK National Health Service (NHS) and after a range of clinical positions, moved first into nursing leadership and then in the late 1980's into general management. Andrew has held several senior executive roles in research-focussed hospitals in both the UK NHS and Australia. He has been a Chief Executive for nearly 25 years, most recently as the CEO of Alfred Health in Melbourne, Victoria, finishing in 2024. Andrew has led several hospitals through clinical and non-clinical digital transformations. Andrew is currently Board Chair of HealthShare Victoria and a Director of Australian College of Health Service Management (ACHSM). He was Interim CEO at the Royal Australian New Zealand College of Psychiatrists between December 2024 and July 2025. He continues to hold a range of other health related advisory roles. He is member of the Risk Committee.
    Mr Michael Sapountzis Company Secretary Mar 2019
    -
    Matthew Gepp Chief Financial Officer
    -
    Michael Sapountzis Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    J P Morgan Nominees Australia Pty Limited 209,178,732 15.58%
    Mr Malcolm Pradhan 116,416,160 8.67%
    Mr Raymond Howard Blight 68,664,657 5.11%
    Bond Street Custodians Limited <Salter D79836 A/C> 50,000,000 3.72%
    Mr Paul John Van Dyk 34,608,937 2.58%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 28,824,376 2.15%
    Rewmicman Pty Ltd <Smallman Family A/C> 27,266,938 2.03%
    Mrs Katrina Elizabeth Doyle 22,793,199 1.70%
    MNMD Pty Ltd <Quirke Super Fund A/C> 20,668,086 1.54%
    Caledonia Nominees Pty Ltd <Caledonia A/C> 19,976,377 1.49%
    Citicorp Nominees Pty Limited 15,222,342 1.13%
    Mr Dean Anthony Mackenzie 14,557,240 1.08%
    Sandhurst Trustees Ltd <Cyan C3G Fund A/C> 11,469,114 0.85%
    Ubs Nominees Pty Ltd 9,840,656 0.73%
    Netwealth Investments Limited <Wrap Services A/C> 8,050,478 0.60%
    Bond Street Custodians Limited <Rsalte D62375 A/C> 8,050,000 0.60%
    Rangiora London Pty Limited <Rangiora London A/C> 7,800,000 0.58%
    Emerald Shares Pty Limited <Emerald Unit A/C> 7,100,000 0.53%
    Mr Vivek Ramakrishnan and Miss Nisha Srinivasan 7,021,913 0.52%
    Mast Financial Pty Ltd <A To Z Investment A/C> 6,425,000 0.48%

    Profile

    since

    Note